Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03624101 · ClinicalTrials.gov registry record · Phase 4
Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT03624101 is a Phase 4 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 1 participants.
The verdict
NCT03624101, a Phase 4 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
Based on previous clinical findings, the investigator hypothesize that ivacaftor will have synergistic effects with drugs that facilitate truncated but partially active W1282X CFTR protein processing (tezacaftor) in patients with W1282X CFTR. In the current study, the investigators propose to directly test the efficacy of tezacaftor/ivacaftor (TEZ/IVA) and Trikafta for W1282X CFTR therapy in the clinic in comparison to ivacaftor alone.
Interventions
- DRUG Symdeko
- DRUG Ivacaftor and Symdeko
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2019-10-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03624101
The ClinicalTrials.gov registry entry for NCT03624101 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Symdeko is the first listed.
NCT03624101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03624101 about?
NCT03624101 is a clinical study titled "Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations". Based on previous clinical findings, the investigator hypothesize that ivacaftor will have synergistic effects with drugs that facilitate truncated but partially active W1282X CFTR protein processing (tezacaftor) in patients with W1282X CFTR. In the current study, the investigators propose to direct...
What is the current status of trial NCT03624101?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2018-12-01. Estimated completion is 2019-10-03.
What interventions are being tested in trial NCT03624101?
The interventions under investigation include: Symdeko (DRUG), Ivacaftor and Symdeko (DRUG).
Who is sponsoring clinical trial NCT03624101?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.